PTC Therapeutics CEO Says Sephience Has Moved To 'Steady, Durable Growth' After Analyst Asks If Launch Is Slowing

CEO Matthew Klein pointed to low-20% cumulative discontinuations and internal data as outside prescription trackers drew scrutiny.

Share
PTC Therapeutics CEO Says Sephience Has Moved To 'Steady, Durable Growth' After Analyst Asks If Launch Is Slowing

PTC Therapeutics CEO Dr. Matthew Klein told analysts on the company's third-quarter earnings call Thursday that Sephience has moved past its early acceleration and into "a steady, durable growth phase," after a Bank of America analyst asked point-blank whether the U.S. launch is slowing. The drug, which treats phenylketonuria (PKU), brought in $182 million worldwide in the quarter, as total revenue reached $358 million.

Pressed on whether the U.S. launch is slowing

PTC Therapeutics is a biopharmaceutical company that develops and sells medicines for rare disorders, mainly in neurology and metabolism. Sephience is its PKU drug, now a year into its global launch.

The Bank of America analyst noted that the ex-U.S. market has more patients but a much lower price, then asked: "is the U.S. launch slowing?" Klein said there was "unquestionably" an acceleration phase in the first few months, and that the company now sees steady growth quarter over quarter. He said that held even through summer seasonality.

He also brushed aside outside efforts to track prescriptions. "When we look at the real data," Klein said, the company sees strong underlying demand and consistent U.S. growth. He said internal metrics keep it on course for a peak opportunity of more than $2 billion.

Asked for the U.S.-versus-international split, Klein said most revenue will come from the U.S. but that it is "hard to have an exact number right now." He put U.S. patients at 17,000 against roughly 41,000 in markets where access is possible.

Low-20% dropouts and a long runway

On persistency, Klein said cumulative discontinuations are around the low 20% range, which he described as near steady state. He expects patients switching from Kuvan, branded or generic, to stay on therapy better than those seen so far.

The company counts more than 2,000 active patients out of about 58,000 people with PKU in its target markets. In the U.S., Klein said at least 85% of PKU patients have not yet tried Sephience, and he put the Kuvan patients who are switch candidates at 2,000 to 2,500.

Third-quarter product revenue was $276 million, against $131 million a year earlier. PTC raised its 2026 product revenue guidance to $960 million to $990 million and now expects total revenue of $1.29 billion to $1.32 billion. Klein said most of the raise comes from Sephience, and he does not expect the Duchenne franchise to contribute as it did earlier in 2026, citing a new generic Emflaza entrant that cut prices.

Germany decision, then Southern Europe

Chief Business Officer Eric Pauwels said pricing talks with Germany's reimbursement body continue, with a decision expected "fairly soon." He said France, Italy and Spain should be finalized in the first half of 2027.

The company also bought Fabry disease gene therapy ST920 in the quarter for $111 million upfront and up to $100 million in milestones tied to U.S. approval. Klein said it could add to earnings in 2027.

Klein said PTC will update investors on its other pipeline programs in January.

Sources

More on PTC Therapeutics

All PTC Therapeutics (PTCT) coverage →